Randomized phase II trial of Everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study - Bachelot, T; Bourgier, C; Cropet, C (J Clin Oncol, 2012)